{
    "clinical_study": {
        "@rank": "52167", 
        "brief_summary": {
            "textblock": "To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number,\n      morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related\n      complex (ARC) patients."
        }, 
        "brief_title": "Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n          -  Stage III or IV HIV infection.\n\n          -  Provide informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Kaposi's sarcoma lesions in the proposed treatment sites.\n\n          -  Liable to require radiation or chemotherapy during the course of the study.\n\n          -  Not likely to survive the length of the study.\n\n          -  Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with\n             recent UV exposure or likely to have such exposure (e.g.:\n\n          -  holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to\n             lidocaine.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other Immunomodulators.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation.\n\n        Patients with the following are excluded:\n\n          -  Kaposi's sarcoma lesions in the proposed treatment sites.\n\n          -  Liable to require radiation or chemotherapy during the course of the study.\n\n          -  Not likely to survive the length of the study.\n\n          -  Obvious ultra-violet-irradiated skin damage in the treatment areas.\n\n          -  Allergy to lidocaine.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior DNCB therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002031", 
            "org_study_id": "047A"
        }, 
        "intervention": {
            "intervention_name": "Dinitrochlorobenzene", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Langerhans Cells", 
            "Dinitrochlorobenzene", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "941102859"
                }, 
                "name": "San Francisco AIDS Clinic / San Francisco Gen Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "1769706", 
            "citation": "Stricker RB, Elswood BF. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Immunol Lett. 1991 Aug;29(3):191-6. Review. Erratum in: Immunol Lett 1992 Aug;33(3):316."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002031"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1990"
    }, 
    "geocoordinates": {
        "San Francisco AIDS Clinic / San Francisco Gen Hosp": "37.775 -122.419"
    }
}